SLC5A2 and heart failure: These favorable changes with empagliflozin were observed despite excellent conventional heart failure therapy, including sacubitril/valsartan in more than one-third of patients, and may explain, at least in part, the improvement in clinical outcomes observed with SGLT2 inhibitors in HFrEF.